A recent observational study conducted in a tertiary intensive care setting in Bosnia and Herzegovina sheds new light on this critical issue by directly comparing two prevalent extracorporeal blood purification systems: CytoSorbⓇ and oXirisⓇ. CytoSorbⓇ operates as a hemoadsorption cartridge integrated into standard CRRT circuits, selectively capturing inflammatory cytokines through adsorption. In contrast, oXirisⓇ utilizes a specialized membrane designed not only to provide renal support but also to facilitate the simultaneous removal of endotoxins and inflammatory mediators through adsorption and filtration mechanisms. This robust study encompassed 97 adult patients diagnosed with septic shock over a one-year period from 2023 to 2024. Researchers meticulously evaluated the impact of each device on patients’ hemodynamic recovery, focusing primarily on vasopressor-free days within the first 28 days post-treatment — a critical metric indicative of shock resolution and patient stabilization.

The findings reveal that both blood purification modalities induced notable hemodynamic improvements, as evidenced by reductions in serum lactate levels, decreased vasopressor dependency, and enhanced blood pressure stabilization following therapy. These objective physiological parameters underscore the potential of extracorporeal blood purification to transiently ameliorate the hemodynamic derangements associated with septic shock. However, despite these encouraging signs, the comparative analysis between CytoSorbⓇ and oXirisⓇ yielded no statistically significant differences in vasopressor-free days. Secondary outcome measurements, including durations of mechanical ventilation, lengths of intensive care unit (ICU) stay, and overall survival rates, similarly demonstrated equivalence between the two treatment arms, suggesting that both modalities may offer comparable clinical benefits in the acute management of septic shock.

The implications of these findings resonate deeply within critical care medicine. The authors emphasize that while extracorporeal blood purification undoubtedly influences key physiological variables, the intricate pathophysiology of sepsis involving persistent mediator production, cellular dysfunction, and dynamic redistribution of inflammatory agents could modulate—or even diminish—the long-term clinical impact of these interventions. Notably, patients subjected to CytoSorbⓇ therapy presented with higher baseline inflammatory markers, which may have confounded direct between-group comparisons and potentially obscured subtle efficacy distinctions. This underscores the complexity of patient heterogeneity in septic shock and highlights the nuanced challenge of tailoring extracorporeal therapies to individual patient profiles.

This study’s retrospective, single-center design inherently introduces certain limitations such as selection bias and potential residual confounding factors not accounted for in the analysis. Additionally, the limited sample size restricts the statistical power necessary to detect more modest but clinically relevant differences. Nevertheless, it represents one of the earliest direct assessments comparing two leading extracorporeal blood purification methods in a real-world clinical context, thus filling a vital knowledge gap. The equivalence observed therein provides a pragmatic perspective for intensivists contemplating these adjunctive therapies, suggesting flexibility in clinical decision-making based on availability, cost considerations, and patient-specific factors without compromising anticipated short-term hemodynamic results.

Looking ahead, the authors advocate for well-designed, larger-scale randomized controlled trials with multicenter collaboration to dissect further which patient subpopulations might derive the greatest benefit from blood purification and to optimize timing and modality selection. Such trials should incorporate comprehensive immunological and biochemical profiling to elucidate mechanistic pathways and refine patient stratification strategies. Integration of cutting-edge biomarker analytic techniques and real-time monitoring may prove instrumental in identifying therapeutic windows and maximizing clinical outcomes. As precision medicine advances, tailoring extracorporeal therapies will likely become integral to the nuanced management of septic shock.

Simultaneously, these findings reinforce a broader principle: while extracorporeal blood purification exerts beneficial short-term stabilizing effects, it is not a panacea for sepsis. Optimal sepsis care continues to rely on a multifaceted approach encompassing early antibiotic therapy, source control, hemodynamic support, and adjunctive strategies targeting underlying pathogen-host interactions. The persistent high mortality in septic shock reflects the complexity and heterogeneity of this syndrome rather than a failure of specific interventions, underscoring the importance of ongoing translational research and clinical innovation.

CytoSorbⓇ and oXirisⓇ, despite their differing technical mechanisms, both embody the evolution of critical care technology aimed at intercepting the deleterious inflammatory cascade. CytoSorbⓇ functions via a polymer bead adsorption system that binds middle molecular weight substances, whereas oXirisⓇ incorporates an AN69 membrane modified for endotoxin adsorption coupled with hemodialytic clearance. Understanding these subtle technological variations enhances clinicians’ ability to select devices aligning with individual pathophysiological demands, treatment goals, and resource availability, which is particularly pivotal in low-income healthcare settings.

In conclusion, this Bosnia and Herzegovina-based study delivers a timely and informative comparison of two pivotal extracorporeal blood purification strategies applied in septic shock management alongside continuous renal replacement therapy. Its results suggest that both CytoSorbⓇ and oXirisⓇ can improve short-term hemodynamics similarly without marked differences in vasopressor independence or survival. These insights provide a foundation for future investigations aiming to refine indications, optimize protocols, and explore integration with broader sepsis therapeutic frameworks. As the quest to unravel sepsis’s complexity persists, embracing evidence-based extracorporeal modalities offers hope for enhancing care quality and patient survival in this globally significant condition.

Subject of Research: People

Article Title: Impact of different extracorporeal blood purification strategies during continuous renal replacement therapy in septic shock patients

News Publication Date: 19-Feb-2026

References: DOI: 10.1016/j.jointm.2025.12.010

Image Credits: Prof. Pedja Kovacevic and Prof. Jihad Mallat from the University of Banja Luka, Bosnia and Herzegovina

Keywords

Septic shock, extracorporeal blood purification, CytoSorbⓇ, oXirisⓇ, continuous renal replacement therapy, cytokine removal, endotoxin adsorption, hemodynamic recovery, critical care, acute kidney injury, vasopressor-free days, intensive care unit

End-stage kidney disease remains a formidable global health challenge, characterized by the irreversible loss of kidney function necessitating life-sustaining dialysis or transplantation. Despite advancements in dialysis technology, mortality rates in this population remain distressingly high, largely due to the burden of retained toxins and systemic inflammation that contribute to cardiovascular complications, infections, and multi-organ dysfunction. Hemodialysis, while effective at clearing small solutes and electrolyte imbalances, has shown limited efficacy in removing larger molecular weight toxins — a gap that hemoadsorption technology aims to fill.

Hemoadsorption involves the use of highly adsorptive materials integrated into extracorporeal circuits to selectively capture and remove circulating middle molecules, inflammatory mediators, and protein-bound toxins implicated in the pathophysiology of ESKD. The rationale behind combining hemoadsorption with hemodialysis lies in the hypothesis that a dual modality approach could deliver a more comprehensive detoxification process, potentially alleviating systemic inflammation and oxidative stress, and thereby reducing mortality. The trial conducted across multiple high-volume nephrology centers rigorously tested this hypothesis by enrolling a diverse patient cohort undergoing maintenance dialysis.

The study embraced an open-label design with random allocation to either combined hemoadsorption plus hemodialysis or hemodialysis alone. The primary endpoint was all-cause mortality, with secondary outcomes assessing cardiovascular events, hospitalization frequency, inflammatory biomarker profiles, and dialysis-related adverse events. By enrolling hundreds of patients and ensuring meticulous follow-up for over a year, the investigators amassed robust statistical power to discern meaningful differences between the treatment arms, offering unprecedented insight into the clinical utility of hemoadsorption.

One of the most striking findings was a statistically significant reduction in mortality in the cohort receiving hemoadsorption adjunctive to hemodialysis. This result not only signals improved survival but also aligns with marked reductions in key inflammatory markers such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and C-reactive protein (CRP). These biomarkers are closely linked to systemic inflammatory cascades that exacerbate vascular injury and cardiac complications in nephropathic patients. By mitigating this inflammatory milieu, the combined therapy may recalibrate immune responses, reduce endothelial dysfunction, and preserve cardiovascular stability.

Digging deeper into mechanistic underpinnings, the authors elucidate that hemoadsorption cartridges employed in the study utilized porous polymer beads with a high surface area designed to adsorb molecules up to approximately 60 kDa. This size range effectively captures cytokines, endotoxins, and other uremic toxins inadequately cleared by standard dialysis membranes. Moreover, the integration of hemoadsorption did not compromise dialysis session durations or vascular access integrity, underscoring the feasibility and safety of this adjunctive approach in routine clinical settings.

Crucially, the trial also reported a significant decrease in hospitalizations and cardiovascular events within the hemoadsorption group, suggesting broad systemic benefits beyond mere toxin clearance. This observation prompts a paradigm shift in understanding ESKD management by targeting inflammation and immune dysregulation as therapeutic axes. Additionally, patient-reported outcomes hinted at improved quality of life metrics, including fatigue reduction and enhanced functional status — dimensions often overshadowed in clinical trials focused largely on biomedical endpoints.

However, the study is not without limitations. The open-label design, while practical for procedural interventions, introduces potential biases that must be considered when interpreting subjective outcomes. Furthermore, long-term effects beyond the 12-month follow-up remain to be investigated to confirm sustained survival benefits and to exclude late-onset complications. The cost-effectiveness of implementing hemoadsorption broadly also warrants economic analyses given the added expenses associated with cartridge use.

The implications of these findings ripple far beyond nephrology. Hemoadsorption has been previously studied in sepsis, cytokine storm syndromes, and cardiac surgery to attenuate inflammatory cascades. Demonstrating efficacy in ESKD expands its therapeutic arsenal and underscores the pivotal role of extracorporeal blood purification in systemic disease modulation. Future research can explore personalization of hemoadsorption protocols based on biomarker phenotypes or integration with novel pharmacotherapies to synergistically improve outcomes.

In an era where precision medicine is increasingly embraced, this trial exemplifies how targeting pathophysiological processes with sophisticated medical devices can transform chronic disease management. Personalized titration of hemoadsorption parameters, innovation in adsorbent materials, and combination with artificial intelligence-driven monitoring could further refine this technology. Moreover, expanding patient selection criteria to include earlier stages of chronic kidney disease may offer preventive benefit and delay progression.

The study also prompts reconsideration of clinical guidelines for dialysis care. Current frameworks emphasize solute clearance and volume management but may need amendment to incorporate anti-inflammatory strategies as a standardized pillar. This holistic approach could reshape multidisciplinary management involving nephrologists, cardiologists, immunologists, and intensivists to optimize survival and quality of life in end-stage kidney disease.

Critically, patient education and shared decision-making remain paramount as technological complexity increases. Understanding the nuances of hemoadsorption, balancing benefits versus procedural burdens, and addressing equity in access to advanced dialysis modalities will be essential to realizing clinical impact. Health systems must prepare for infrastructural adaptations and training to integrate hemoadsorption seamlessly.

Finally, the broader scientific and medical community will keenly watch for results from ongoing or future trials validating these findings across diverse populations and healthcare settings. Replication studies, meta-analyses, and registries capturing real-world data will further confirm the role of hemoadsorption combined with hemodialysis as a new standard in ESKD care. If these results withstand scrutiny and implementation challenges, this innovation heralds a new chapter that promises to fundamentally shift the prognosis of one of nephrology’s most refractory conditions.

Subject of Research: Mortality outcomes in end-stage kidney disease patients receiving hemoadsorption combined with hemodialysis versus hemodialysis alone.

Article Title: Hemoadsorption combined with hemodialysis versus hemodialysis alone on mortality in end-stage kidney disease: a randomized, open-label, multicenter trial.

Article References:
Lu, W., Zhang, X., Guo, Z. et al. Hemoadsorption combined with hemodialysis versus hemodialysis alone on mortality in end-stage kidney disease: a randomized, open-label, multicenter trial. Nat Commun (2026). https://doi.org/10.1038/s41467-026-71079-7

Image Credits: AI Generated

DOI: 10.1038/s41467-026-71079-7

Keywords: Hemoadsorption, Hemodialysis, End-stage kidney disease, Mortality, Inflammation, Extracorporeal blood purification, Cytokine removal, Clinical trial